Astellas Pharma Inc. has taken an exclusive option to license DAX-044 from Melbourne, Australia-based Audax Biosciences, formerly Onko-innate, in a deal worth up to $1.34 billion, backing the…
Astellas Pharma Inc. has taken an exclusive option to license DAX-044 from Melbourne, Australia-based Audax Biosciences, formerly Onko-innate, in a deal worth up to $1.34 billion, backing the Australian biotech’s longstanding strategy to harness interleukin-12 (IL-12) against tumors while limiting systemic immune activation.
Source disclosure
This is a source-linked briefing. Read the original report from Bioworld .